Barclays
RYTM icon

Barclays’s Rhythm Pharmaceuticals RYTM Stock Holding History

Barclays’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-5,600
Closed -$230K – 5447
2024
Q2 		$230K Hold
5,600
– – ﹤0.01% 3506
2024
Q1 		$243K Hold
5,600
– – ﹤0.01% 4009
2023
Q4 		$257K Buy
+5,600
New +$177K ﹤0.01% 4307

Other funds holding RYTM

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $109B AUM 51.53% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Barclays's RYTM Position: Q3 2026 in Review

Barclays increased its Rhythm Pharmaceuticals (RYTM) stake by 181% in Q3 2026, buying an estimated $2.55M and bringing the position to 37,080 shares worth $3.53M. The position accounts for ﹤0.01% of the portfolio, ranked #2232.

Barclays first reported a position in RYTM in Q4 2017 and has held it in 36 quarters since. The position peaked at $22.2M in Q2 2025. 148 funds tracked by Wall St. Rank hold RYTM as of Q3 2026.

  • Barclays held 37,080 shares of Rhythm Pharmaceuticals worth $3.53M as of Q3 2026.
  • Barclays bought 23,871 Rhythm Pharmaceuticals shares in Q3 2026, an estimated $2.55M.
  • Rhythm Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #2232 holding.
  • Barclays first reported a position in Rhythm Pharmaceuticals in Q4 2017 and has held it in 36 quarters since.
  • Barclays's Rhythm Pharmaceuticals position peaked at $22.2M in Q2 2025.
  • 148 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.